Postprandial gastrokinetic agent
AssigneesZeria Pharmaceutical Co., Ltd., Saitama University
InventorsTakafumi SAKAI, Ichiro SAKATA, Kayuri KURODA, Makoto YOSHIMURA
Life of this patent
Estimating the term…
Abstract
To provide a therapeutic agent for gastrointestinal disorder such as diabetic gastroparesis. A postprandial gastrokinetic agent containing (A) ghrelin or a ghrelin agonist and (B) motilin or a motilin agonist as active ingredients, in which both the ingredients (A) and (B) are administered so as to act on the stomach after food intake.
Claims15
A postprandial gastrokinetic agent, comprising:
- (A) ghrelin or a ghrelin agonist and (B) motilin or a motilin agonist as active ingredients.
A method for enhancing postprandial gastric motility, comprising:
- administering an ingredient (A) which is ghrelin or a ghrelin agonist and an ingredient (B) which is motilin or a motilin agonist to a subject in need thereof such that an effective blood level of each of the ingredients (A) and (B) is achieved after food intake,
- wherein after food intake is within about 30 minutes immediately after intake of a meal, and
- timing of the administering of each of the ingredients (A) and (B) is determined in consideration of a time to achieve the effective blood level, which is about 20 minutes to about 60 minutes after oral administration and about 10 minutes after intravenous administration.
A method of treating a human patient having a disease selected from the group consisting of diabetic gastroparesis, postoperative gastroparesis, and functional dyspepsia, comprising:
- administering ghrelin or a ghrelin agonist and motilin or a motilin agonist to the human patient.
Dependencies are inferred from the claim text.